ELOX · Eloxx Pharmaceuticals, Inc.

Eloxx Pharmaceuticals secured supermajority stockholder approval via written consent for significant governance changes that enhance equity compensation flexibility and adjust capital structure. The amendments to the 2018 Equity Incentive Plan substantially increase available shares for awards to 20 million and the ISO limit to 30 million, followed by a restatement extending grant periods and the evergreen provision, enabling greater retention and incentive alignment for employees and executives amid potential growth needs. Concurrently, approval for a Board-determined reverse stock split (1:2 to 1:20) within one year provides tools to address share price or listing concerns, while reducing authorized common stock to 100 million from 500 million streamlines the capital structure and signals fiscal prudence. These actions, supported by 57.1% of outstanding shares on the Record Date, underscore strong insider or aligned holder backing but await effectiveness post definitive Schedule 14C dissemination and 20-day waiting period under Rule 14c-2, ensuring regulatory compliance before implementation.